ONE Bio Corp. (ONBI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2010 | 52.29 Million USD | 136.92% |
| 2009 | 22.07 Million USD | 28112.19% |
| 2008 | 78.24 Thousand USD | -86.48% |
| 2007 | 578.59 Thousand USD | 178.83% |
| 2006 | 207.5 Thousand USD | 26.7% |
| 2005 | 163.78 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2011 Q1 | 12.08 Million USD | -19.19% |
| 2011 Q3 | 13.54 Million USD | 1.5% |
| 2011 Q2 | 13.33 Million USD | 10.42% |
| 2010 Q4 | 14.94 Million USD | 10.69% |
| 2010 Q3 | 13.5 Million USD | 6.51% |
| 2010 FY | 52.29 Million USD | 136.92% |
| 2010 Q1 | 11.16 Million USD | -17.0% |
| 2010 Q2 | 12.67 Million USD | 13.59% |
| 2009 FY | 22.07 Million USD | 28112.19% |
| 2009 Q4 | 13.44 Million USD | 223.44% |
| 2009 Q3 | 4.15 Million USD | 646726.13% |
| 2009 Q1 | 7819.00 USD | -78.3% |
| 2009 Q2 | -643.00 USD | -108.22% |
| 2008 Q1 | 29.95 Thousand USD | -93.3% |
| 2008 FY | 78.24 Thousand USD | -86.48% |
| 2008 Q4 | 36.03 Thousand USD | 2411.48% |
| 2008 Q2 | 13.8 Thousand USD | -53.9% |
| 2008 Q3 | -1559.00 USD | -111.29% |
| 2007 FY | 578.59 Thousand USD | 178.83% |
| 2007 Q4 | 447.23 Thousand USD | 619.94% |
| 2007 Q1 | 34.33 Thousand USD | -55.83% |
| 2007 Q3 | 62.12 Thousand USD | 78.01% |
| 2007 Q2 | 34.89 Thousand USD | 1.63% |
| 2006 Q1 | 28.54 Thousand USD | 0.0% |
| 2006 Q2 | 31.94 Thousand USD | 11.93% |
| 2006 Q3 | 69.28 Thousand USD | 116.85% |
| 2006 Q4 | 77.73 Thousand USD | 12.2% |
| 2006 FY | 207.5 Thousand USD | 26.7% |
| 2005 FY | 163.78 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -68961.596% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -187.058% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | 57.467% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -2606.843% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -231.555% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -296683.4% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -143.487% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -79464.574% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -786.076% |
| Marizyme, Inc. | 645.81 Thousand USD | -7997.769% |
| Genus plc | 668.8 Million USD | 92.181% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 78.682% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -52727.649% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -12650.04% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -68028.611% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -132235.146% |
| MultiCell Technologies, Inc. | 49.32 USD | -106034374.858% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -5.179% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -106845.2% |
| Q BioMed Inc. | 284.35 Thousand USD | -18291.361% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -76.694% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | 63.958% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -9276.953% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -74608.861% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -7841.716% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 99.644% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -5234755.155% |
| Enzolytics Inc. | 52.79 Thousand USD | -98953.343% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -8493.928% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 95.736% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -37189.972% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -8370.612% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 93.771% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -5141.54% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -8.153% |
| BioStem Technologies, Inc. | 16.68 Million USD | -213.425% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -22006.951% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -22006.951% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -3720.029% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -10939.242% |
| SYBLEU INC | 11.69 Thousand USD | -447028.959% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -571.411% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -402178.485% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -132181.588% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -1470.457% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -684.639% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -4933.321% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -102.958% |
| CSL Limited | 14.8 Billion USD | 99.647% |
| Cellectis S.A. | 755 Thousand USD | -6826.649% |